Long-term therapy with non-steroidal anti-inflammatory drugs for axial spondyloarthritis: focus on changes in liver function
https://doi.org/10.31146/1682-8658-ecg-187-3-152-157
Abstract
The purpose of the study is to analyze the state of liver function in patients with spondyloarthritis taking non-steroidal anti-inflammatory drugs continuously for 24 months. Materials and methods of the study include 198 patients with spondyloarthritis. The prospective study involved 36 patients with spondyloarthritis who took non-steroidal anti-inflammatory drugs (NSAIDs) prescribed by a physician in the community for 24 months. The level of liver enzymes in blood serum at admission and in dynamics was studied. The increase of liver enzymes was detected in 12 (6.06%) of 198 patients with spondyloarthritis. Among them 6 (50%) patients took methotrexate, 1 (8.33%) - genetically engineered drug, 2 (16.67%) patients-sulfasalazine and 3 (25%) - nonsteroidal anti - inflammatory drugs. 19.4% of patients were registered with a periodic increase of transaminase levels on the background of NSAIDs for the last 24 months. At the same time, no cases of acute liver damage or progressive deterioration of liver function requiring discontinuation of therapy were recorded during the entire follow-up period.
About the Authors
A. P. Rebrov
Saratov State Medical University named after V. I. Razumovsky
Russian Federation
Russian Federation
A. V. Aparkina
Saratov State Medical University named after V. I. Razumovsky
Russian Federation
Russian Federation
E. V. Kchondkaryan
Saratov State Medical University named after V. I. Razumovsky
Russian Federation
Russian Federation
References
1. van der Heijden D., Ramiro S., Landewé R. et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017, vol. 76, pp. 978-991.
2. Gaidukova I.Z., Rebrov A. P., Korotaeva T. V., et al. Remission in axial spondyloarthritis: Definition and evaluation tools (recommendations of the Spondyloarthritis Study Group of Experts, All-Russian Public Organization “The Association of Rheumatology of Russia”). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice, 2018, vol. 56, no.1, pp. 10-14 (In Russ.) doi: 10.14412/1995-4484-2018-10-14@@ Гайдукова И. З., Ребров А. П., Коротаева Т. В. и др. Ремиссия при аксиальных спондилоартритах - определение и инструменты оценки (рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России»). Научно-практическая ревматология. - 2018 - Т. 56. - № 1. - С. 10-14.
3. R. J. Lories, F. P. Luyten, К. de Vlam. Progress in spondyloarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthr research & therapy. 2009, vol. 11, no. 2, pp. 221. doi:10.1186/ar2642.
4. D. Poddubnyy, D. van der Heijde. Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs. Rheum Dis Clin North Am. 2012, vol. 38, no. 3, pp. 601-611.
5. Donati M., Conforti A., Lenti M. C., et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. Br J Clin Pharmacol. 2016, vol. 82, no. 1, pp. 238-248. doi: 10.1111/bcp.12938. Epub 2016 Apr 27.
6. Abdulganieva D. I. Features of patients with NSAIDs-induced gastropathy. Klinicheskie perspektivy gastroenterologii, gepatologii, 2011, no. 6, pp. 23-29. (In Russ.)@@ Абдулганиева Д. И. Особенности ведения больных с НПВП-индуцированной гастропатией. Клинические перспективы гастроэнтерологии, гепатологии. - 2011. - № 6. - с. 23-29.
7. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol. 2010, vol. 16, no. 45, pp. 5651-5661.
8. Lukas C., Landewe R., Sieper J., et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009, vol. 68, no.1, pp. 18-24. doi: 10.1136/ard.2008.094870. Epub 2008 Jul 14.
9. Garrett S., Jenkinson T., Kennedy L. G., et al. New approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994, vol. 21, no.12, pp. 2286-2291.
10. Wells G., Becker J.C, Teng J., et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009, vol. 68, no. 6, pp. 954-960. doi: 10.1136/ard. 2007.084459. Epub 2008 May 19.
11. Smolen J.S., Braun J., Dougados M., et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014, vol. 73, no. 1, pp. 6-16. doi: 10.1136/annrheumdis-2013-203419. Epub 2013 Jun 8.
12. Karateev A.E., Erdes Sh. F. The use of nonsteroidal antiinflammatory drugs in ankylosing spondylitis: long and hard! Terapevticheskii arkhiv. 2014, vol. 86, no. 11, pp. 123-127. (In Russ.)@@ Каратеев А. Е., Эрдес Ш. Ф. Применение нестероидных противовоспалительных препаратов при анкилозирующем спондилите: долго и упорно! Терапевтический архив. - 2014. - T. 86. - № 11- с. 123-127.
13. Gaidukova I.Z., Rebrov A. P., Otteva E. N., et al. Use of nonsteroidal anti-inflammatory drugs for the treatment of axial spondyloarthritis, including ankylosing spondylitis, monitoring their efficacy and safety (draft guidelines of the expert spondyloarthritis diagnosis and treatment group). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2016, vol. 54, no. 1, pp. 67-74. (In Russ.). doi: 10.14412/1995-4484-2016-1S-67-74@@ Гайдукова И. З., Ребров А. П., Оттева Э. Н. и др. Применение нестероидных противовоспалительных препаратов для лечения аксиальных спондилоартритов, включая анкилозирующий спондилит, мониторинг эффективности и безопасности (проект рекомендации группы экспертов по диагностике и лечению спондилоартритов). Научно-практическая ревматология. - 2016. - Т. 54. - № 1. - c. 67-74.
14. Rebrov A.P., Gaidukova I. Z., Polyanskaya O. G., Spitsina M. Yu. Prolonged use of nimesulide in real clinical practice: security issues. Russkii meditsinskii zhurnal. 2013, vol. 21, no. 9, pp. 433-437. (In Russ.)@@ Ребров А. П., Гайдукова И. З., Полянская О. Г. и др. Длительное применение нимесулида в реальной клинической практике: вопросы безопасности. Русский медицинский журнал. -2013- Т. 21. - № 9 - с. 433-437.
15. Jessurun N., van Puijenbroek E. Relationship between structural alerts in NSAIDs and idiosyncratic hepatotoxicity: an analysis of spontaneous report data from the WHO database. Drug Saf. 2015 May, vol. 38, no. 5, pp. 511-515. doi: 10.1007/s40264-015-0282-z
16. Tujios S., Fontana R. J. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol. 2011, vol. 8, no. 4, pp. 202-211. doi: 10.1038/nrgastro.2011.22. Epub 2011 Mar 8.
17. Jaeschke H., Williams C. D., McGill M. R. Caveats of using acetaminophen hepatotoxicity models for natural product testing. Toxicol Lett. 2012, vol. 215, no. 1, pp. 40-41. doi: 10.1016/j.toxlet.2012.09.023. Epub 2012 Oct 4
18. Braun J., van den Berg R., Baraliakos X. et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011, vol. 70, no. 6, pp. 896-904.
19. Patrignani P., Capone M. L., Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin Pharmacother. 2003, vol. 4, no. 2, pp. 265-284.
20. Hur C., Chan A. T., Tramontano A. C., Gazelle G. S. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs. Ann Pharmacother. 2006, vol. 40, no. 6, pp. 1052-1063.
21. Maquirriain J., Kokalj A. Management of acute Achilles tendinopathy: effect of etoricoxib on pain control and leg stiffness. Georgian Med News. 2013, vol. 222, pp. 36-43.
Review
For citations:
Rebrov A.P., Aparkina A.V., Kchondkaryan E.V. Long-term therapy with non-steroidal anti-inflammatory drugs for axial spondyloarthritis: focus on changes in liver function. Experimental and Clinical Gastroenterology. 2021;(3):152-157. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-187-3-152-157
Views:
334
Email this article 